Markets Insider: Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With ...
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With ...
Seeking Alpha: Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid ...
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC ...
Nasdaq: Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
Nasdaq: Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
pharmaphorum: From preclinical toxicology to clinical safety: The path for oncology IND submissions
From preclinical toxicology to clinical safety: The path for oncology IND submissions
Seeking Alpha: Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence
Clarivate Introduces New OFF-X ™ Platform for Preclinical and Clinical Safety Intelligence
Morningstar: Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial
Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial